Eradication of Helicobacter pylori in functional dyspepsia

BMJ 1999;319:451 ( 14 August )

Letters

Eradication of Helicobacter pylori in functional dyspepsia

Study had several weaknesses

Authors' reply

Study had several weaknesses

The first 150 words of the full text of this article appear below.

EDITOR $---$ Several weaknesses in Talley et al's study may explain its failure to detect symptomatic benefit from eradicating infectionwith Helicobacter pylori in functional dyspepsia.¹ The firstis inadequate follow up. Of the three quarters of patients saidto have completed the study, some did not reach their one yearassessment. The outcome measurement even in those reaching theone year end point seems to have been inadequate as symptom diarycards in which only three fifths were completed were consideredacceptable. The proportion of randomised patients reaching theone year end point with complete outcome documentation needs tobereported.

In our study, funded by the Medical Research Council, 318 patients were randomised and 97% were fully reassessed one yearafter treatment.² This reassessment showed a significant benefitof active compared with placebo treatment of 14% (95% confidenceinterval 7% to 22%; P<0.001). Even before the problems with follow. . . [Full text of this article]

CiteULike

Complore

Connotea

Del.icio.us Add to Digg

Digg

StumbleUpon Add to Technorati

Technorati What's this?

Relevant Article

Eradication of Helicobacter pylori in functional dyspepsia: randomised double blind placebo controlled trial with 12 months' follow up: Nicholas J Talley, Jef Janssens, Karsten Lauritsen, István Rácz, and Elisabeth Bolling-Sternevald
BMJ 1999 318: 833-837. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

Moayyedi, P., Soo, S., Deeks, J., Forman, D., Mason, J., Innes, M., Delaney, B. (2000). Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. BMJ 321: 659-664 [Abstract] [Full text]